Blomen, C.L.; Kött, J.; Hartung, T.I.; Torster, L.K.; Gebhardt, C.
Combination of Immune Checkpoint Inhibitors and Liver-Specific Therapies in Liver-Metastatic Uveal Melanoma: Can We Thus Overcome Its High Resistance? Cancers 2021, 13, 6390.
https://doi.org/10.3390/cancers13246390
AMA Style
Blomen CL, Kött J, Hartung TI, Torster LK, Gebhardt C.
Combination of Immune Checkpoint Inhibitors and Liver-Specific Therapies in Liver-Metastatic Uveal Melanoma: Can We Thus Overcome Its High Resistance? Cancers. 2021; 13(24):6390.
https://doi.org/10.3390/cancers13246390
Chicago/Turabian Style
Blomen, Chiara L., Julian Kött, Tabea I. Hartung, Leopold K. Torster, and Christoffer Gebhardt.
2021. "Combination of Immune Checkpoint Inhibitors and Liver-Specific Therapies in Liver-Metastatic Uveal Melanoma: Can We Thus Overcome Its High Resistance?" Cancers 13, no. 24: 6390.
https://doi.org/10.3390/cancers13246390
APA Style
Blomen, C. L., Kött, J., Hartung, T. I., Torster, L. K., & Gebhardt, C.
(2021). Combination of Immune Checkpoint Inhibitors and Liver-Specific Therapies in Liver-Metastatic Uveal Melanoma: Can We Thus Overcome Its High Resistance? Cancers, 13(24), 6390.
https://doi.org/10.3390/cancers13246390